- Home
- LPBB vs ITOS Comparison
LPBB vs ITOS Comparison
Compare LPBB & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPBB
- ITOS
- Stock Information
- Founded
- LPBB 2024
- ITOS 2011
- Country
- LPBB United States
- ITOS United States
- Employees
- LPBB N/A
- ITOS N/A
- Industry
- LPBB
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPBB
- ITOS Health Care
- Exchange
- LPBB NYSE
- ITOS Nasdaq
- Market Cap
- LPBB 289.8M
- ITOS 270.7M
- IPO Year
- LPBB 2024
- ITOS 2020
- Fundamental
- Price
- LPBB $10.29
- ITOS $6.70
- Analyst Decision
- LPBB
- ITOS Strong Buy
- Analyst Count
- LPBB 0
- ITOS 3
- Target Price
- LPBB N/A
- ITOS $25.67
- AVG Volume (30 Days)
- LPBB 71.1K
- ITOS 553.7K
- Earning Date
- LPBB 01-01-0001
- ITOS 04-28-2025
- Dividend Yield
- LPBB N/A
- ITOS N/A
- EPS Growth
- LPBB N/A
- ITOS N/A
- EPS
- LPBB 0.16
- ITOS N/A
- Revenue
- LPBB N/A
- ITOS $35,000,000.00
- Revenue This Year
- LPBB N/A
- ITOS N/A
- Revenue Next Year
- LPBB N/A
- ITOS $31.74
- P/E Ratio
- LPBB $62.80
- ITOS N/A
- Revenue Growth
- LPBB N/A
- ITOS 177.89
- 52 Week Low
- LPBB $9.89
- ITOS $4.80
- 52 Week High
- LPBB $11.06
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- LPBB N/A
- ITOS 49.45
- Support Level
- LPBB N/A
- ITOS $6.58
- Resistance Level
- LPBB N/A
- ITOS $7.80
- Average True Range (ATR)
- LPBB 0.00
- ITOS 0.51
- MACD
- LPBB 0.00
- ITOS -0.03
- Stochastic Oscillator
- LPBB 0.00
- ITOS 32.10
About LPBB LAUNCH TWO ACQUISITION CORP
Launch Two Acquisition Corp is a blank check company.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.